Skip to main content
Retour
Watch Compare

Skye Bioscience, Inc.

Qualité des données : 83%
SKYE
Nasdaq Manufacturing Chemicals
0,73 €
▲ 0,02 € (2,52%)
Cap. Boursière: 24,20 M
Prix
0,73 €
Cap. Boursière
24,20 M
Fourchette du Jour
0,69 € — 0,73 €
Fourchette 52 Semaines
0,57 € — 5,75 €
Volume
68 449
Ouverture 0,70 €
Moyenne 50J / 200J
0,76 €
4,59% below
Moyenne 50J / 200J
2,07 €
64,97% below

Quick Summary

Points Clés

Negative free cash flow of -43,07 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-146,18%
En dessous de la moyenne du secteur (-53,47%)
ROIC-119,65%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio4,77
Interest CoverageN/A

Valorisation

PE (TTM)
-0,43
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio0,74
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,4 -1,5
P/B 0,7 1,6
ROE % -146,2 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BRSIX BRSIX
0,07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -55,92 M
ROE -146,18% ROA -119,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -43,07 M
ROIC -119,65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,77
Interest Coverage N/A Asset Turnover N/A
Working Capital 31,56 M Tangible Book Value 32,84 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,43 Forward P/E N/A
P/B Ratio 0,74 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -177,97%
Market Cap 24,20 M Enterprise Value 5,76 M
Per Share
EPS (Diluted TTM) -1,41 Revenue / Share N/A
FCF / Share -1,29 OCF / Share -1,29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 77,01%
SBC-Adj. FCF -51,14 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -55,92 M -26,57 M -37,64 M -19,48 M -8,52 M
EPS (Diluted) -1,41 -0,73 -5,37 -0,04 -0,02
Gross Profit — — — — —
Operating Income -58,16 M -30,19 M -34,74 M -18,31 M -7,85 M
EBITDA — — — — —
R&D Expenses — — — 6,01 M 2,93 M
SG&A Expenses — — — — —
D&A 723 352,0 298 640,0 — — —
Interest Expense 0,0 749 308,0 906 270,0 665 133,0 769 159,0
Income Tax 5 400,0 10 071,0 3 600,0 6 741,0 2 100,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 28,31 M 72,76 M 11,94 M 9,11 M 9,86 M
Total Liabilities 8,29 M 4,61 M 14,07 M 12,12 M 3,99 M
Shareholders' Equity 20,02 M 68,15 M -2,13 M -3,01 M 5,86 M
Total Debt — — — — —
Cash & Equivalents 5,88 M 68,42 M — — —
Current Assets 27,09 M 70,83 M 11,65 M 8,94 M 9,61 M
Current Liabilities 8,21 M 4,34 M 13,90 M 12,12 M 3,91 M